We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.05 | -5.71% | 0.825 | 2,774,653 | 15:19:35 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.80 | 0.85 | 0.90 | 0.825 | 0.90 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 543k | -609k | -0.0030 | -2.73 | 1.78M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:49:07 | O | 118,573 | 0.84 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 10/1/2025 | 07:00 | UK RNS | Physiomics PLC Publication of Peer Reviewed Article |
| 08/1/2025 | 15:10 | ALNC |  Physiomics shares rise as dosing software project gains key approvals |
| 08/1/2025 | 09:00 | UK RNS | Physiomics PLC Clinical Trial Approval |
| 12/12/2024 | 12:00 | UK RNS | Physiomics PLC Contract Award |
| 05/12/2024 | 19:52 | ALNC | EARNINGS AND TRADING: Synectics deal wins; TruFin to beat expectations |
| 05/12/2024 | 07:52 | ALNC | *Physiomics says new contract will inform treatment of novel cancer.. |
| 05/12/2024 | 07:00 | UK RNS | Physiomics PLC Contract Award |
| 19/11/2024 | 16:50 | UK RNS | Physiomics PLC Result of AGM |
| 08/11/2024 | 07:00 | UK RNS | Physiomics PLC Director Dealing |
| 04/11/2024 | 07:00 | UK RNS | Physiomics PLC Senior Management Announcement |
Physiomics (PYC) Share Charts1 Year Physiomics Chart |
|
1 Month Physiomics Chart |
Intraday Physiomics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 17/1/2025 | 20:13 | Physiomics - Cancer Treatment tech firm working with Merck + Oxford Uni | 11,664 |
| 17/6/2021 | 06:23 | PHYSIOMICS plc Virtual Tumor platform | 4,957 |
| 28/3/2021 | 21:05 | Physiomics PYC 2021 DISCUSSION (MODERATED) | 5 |
| 22/12/2020 | 11:36 | 3 Years ago today | 2 |
| 29/11/2020 | 14:53 | 3 Years ago today | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 18/1/2025 08:20 by Physiomics Daily Update Physiomics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker PYC. The last closing price for Physiomics was 0.88p.Physiomics currently has 203,210,000 shares in issue. The market capitalisation of Physiomics is £1,666,322. Physiomics has a price to earnings ratio (PE ratio) of -2.73. This morning PYC shares opened at 0.90p |
Posted at 08/1/2025 15:15 by troutisout As far as I can see, the trial has already had grant funding back in 2023, it was just awaiting approvals to commence. They have a Clinical Nurse in place and don't seem to think it will take too long to recruit patients for the trial.However this is where I am confused as many here sought to say that the dosing software was being used in the trial, but reading and re-reading the RNS suggests this is an observational trial and that the data received from patient would then be used to develop and refine the PYC dosing software. So does this mean they aren't using the software to dose the patients, just the data from the trial to try and evaluate/refine the dosing software? "The Project, being run in partnership with Beyond Blood Diagnostics Limited ("Beyond Blood Diagnostics") and Blackpool Teaching Hospitals NHS Foundation Trust ("Blackpool Teaching Hospitals") will recruit breast cancer patients undergoing standard of care GCSF treatment onto an observational clinical trial in order to predict and measure the effect treatment has on neutropenia. The data resulting from this trial will support the refinement and evaluation of the software." |
Posted at 08/1/2025 06:52 by ravenrussia Had a quick look this morningBig difference is TCF is pre revenue stage whereas PYC delivering £1mln year revenues Also PYC annual losses about £400,000 whereas TCF half year £1mln (full year £2mln) but I will certainly take a look as don't know anything about TCF Financial highlights · Financial performance in line with expectations: o Post-tax loss of £1.1m (2023: £1.5m) o Cash outflow from operations of £1.1m (2023: £1.3m) o Cash deposits, cash and cash equivalents balance on 30 September 2024 of £1.2m (30 September 2023: £3.7m) · Cash runway unchanged to end of 2025 excluding any potential milestone payments. Dr Huw Jones, Chief Executive Officer of TheraCryf, s |
Posted at 07/1/2025 22:47 by thiopia Comparing TCF and PYC for upside potentialTCF - Theracryf PYC - Physiomics TCF - share price 0.75p Mkt Cap £3m PYC - share price 0.75p Mkt Cap £1.5m Potential Catalysts ? PYC - consulting contracts ? software/IP development with partners such as DoseMeRX / Beyond Blood Diagnostics ? Government grants to run NHS trials ? TCF - has an existing $160m deal with Stalicla where a $0.5m milestone payment has been due/overdue for 12 months and another $5m milestone could be imminent for their Autism candidate. TCF claim to be in amicable discussions with Stalicla to resolve this issue. $0.5m would be very meaningful to a £3m company. $5m utterly transformational. 52 week high as of (Jan 2025) TCF - 1.85p PYC - 1.85p Charting w.r.t 50/200 day Moving Averages TCF is currently above the 50 and 200 day Moving Averages PYC is currently in between narrowing 50 and 200 Moving Averages |
Posted at 06/1/2025 19:23 by ravenrussia Clearly TMK hadn't got a hobby or new investment for ChristmasApparently you're also connected to a vile character from PYC telegram group Makes sense now |
Posted at 01/1/2025 21:39 by 1347 PYC is a waste of time, companies that have some IPR don't do placings with huge discounts. They've never achieved anything of significance, just doing corner shop type consultancy. |
Posted at 01/1/2025 19:44 by ravenrussia Very strong claim to say major fraudI hope you have evidence for that as this will passed on to ADVFN and PYC lawyers The deal for VAL /PYC i have just read tonight, and has been passed by both sets of NOMAD and yet you call it a fraud. |
Posted at 14/12/2024 09:59 by ravenrussia £20 Million MCAP suggestion is peanuts. More like £200 Million for starters in our space, when you read the PWC's dealmaker report on our sector.. It makes for interesting reading. See below for a summary of why PYC is so under valued:1. Dealmakers in pharmaceuticals and life sciences and in healthcare services are eager to get deals done. 2. Competition for truly innovative assets remains intense. 3. Large pharmaceutical companies will continue to pursue biotech targets and products that can offset revenue declines from lost exclusivity in the coming years. 4. Companies seeking opportunities to digitalise through implementation of analytics technology, digital direct-to-consumer therapeutics offerings, smart health devices and other software innovations will continue to acquire or partner with data and analytics and other technology companies that can deliver these digital solutions. For example: 5. Merck: Acquired Harpoon Therapeutics for an estimated $680 million 6. Novartis: Acquired Calypso Biotech for $250 million 7. Aditxt: Acquired Evofem Biosciences for $100 million 8. There were 420 M&A deals in our sector globally in Q3 2024, worth a total value of $32.4bn. Source: GlobalData’s Deals Database. 9. The $3.2bn acquisition of Morphic Holdings by Eli Lilly and Co was the industry’s largest disclosed deal in Q3 2024. 10. Interestingly for PYC investors AI / State of the art virtual technology accounted for 11 pharmaceutical deals announced in Q3 2024, worth a total value of $1.7bn. The $1.1bn acquisition of Integrated Oncology Network by Cardinal Health was the industry’s largest disclosed deal. hxxps://www.pwc.com/ |
Posted at 13/12/2024 07:49 by tees maar khan The share price is meandering sideways since early July. It had a little spike towards the beginning of August? but to no avail. There's been no real signs of any progress even from a TA perspective.TMK |
Posted at 01/10/2024 11:43 by davevt Raven, right, so it's currently priced into the current share price, as it's foreknowledge. |
Posted at 30/9/2024 16:19 by davevt Raven, so if we already know the expected turnover is going to be 1.7m, that's now priced into the share price, as it's public knowledge. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
